BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 33734413)

  • 1. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020.
    Landry JP; Schertz KL; Chiang YJ; Bhalla AD; Yi M; Keung EZ; Scally CP; Feig BW; Hunt KK; Roland CL; Guadagnolo A; Bishop AJ; Lazar AJ; Slopis JM; McCutcheon IE; Torres KE
    JAMA Netw Open; 2021 Mar; 4(3):e210945. PubMed ID: 33734413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
    Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
    J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors.
    LaFemina J; Qin LX; Moraco NH; Antonescu CR; Fields RC; Crago AM; Brennan MF; Singer S
    Ann Surg Oncol; 2013 Jan; 20(1):66-72. PubMed ID: 22878618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO).
    Valentin T; Le Cesne A; Ray-Coquard I; Italiano A; Decanter G; Bompas E; Isambert N; Thariat J; Linassier C; Bertucci F; Bay JO; Bellesoeur A; Penel N; Le Guellec S; Filleron T; Chevreau C
    Eur J Cancer; 2016 Mar; 56():77-84. PubMed ID: 26824706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant peripheral nerve sheath tumours in neurofibromatosis 1.
    Evans DG; Baser ME; McGaughran J; Sharif S; Howard E; Moran A
    J Med Genet; 2002 May; 39(5):311-4. PubMed ID: 12011145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1.
    McCaughan JA; Holloway SM; Davidson R; Lam WW
    J Med Genet; 2007 Jul; 44(7):463-6. PubMed ID: 17327286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between benign and malignant peripheral nerve sheath tumors in NF1.
    Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
    Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
    Friedrich RE; Beer C; Glatzel M; Hagel C
    Anticancer Res; 2015 Jan; 35(1):137-44. PubMed ID: 25550544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children.
    Friedrich RE; Hartmann M; Mautner VF
    Anticancer Res; 2007; 27(4A):1957-60. PubMed ID: 17649804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1.
    McPherson JR; Ong CK; Ng CC; Rajasegaran V; Heng HL; Yu WS; Tan BK; Madhukumar P; Teo MC; Ngeow J; Thike AA; Rozen SG; Tan PH; Lee AS; Teh BT; Yap YS
    Cancer Med; 2015 Dec; 4(12):1871-8. PubMed ID: 26432421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Nguyen R; Jett K; Harris GJ; Cai W; Friedman JM; Mautner VF
    J Neurooncol; 2014 Jan; 116(2):307-13. PubMed ID: 24166582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
    Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
    Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study.
    Martin E; Coert JH; Flucke UE; Slooff WM; van de Sande MAJ; van Noesel MM; Grünhagen DJ; Wijnen MHWA; Verhoef C
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28138. PubMed ID: 31889416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.
    Kolberg M; Høland M; Agesen TH; Brekke HR; Liestøl K; Hall KS; Mertens F; Picci P; Smeland S; Lothe RA
    Neuro Oncol; 2013 Feb; 15(2):135-47. PubMed ID: 23161774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.
    Zou C; Smith KD; Liu J; Lahat G; Myers S; Wang WL; Zhang W; McCutcheon IE; Slopis JM; Lazar AJ; Pollock RE; Lev D
    Ann Surg; 2009 Jun; 249(6):1014-22. PubMed ID: 19474676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
    Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France.
    Duong TA; Sbidian E; Valeyrie-Allanore L; Vialette C; Ferkal S; Hadj-Rabia S; Glorion C; Lyonnet S; Zerah M; Kemlin I; Rodriguez D; Bastuji-Garin S; Wolkenstein P
    Orphanet J Rare Dis; 2011 May; 6():18. PubMed ID: 21542925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.
    Mautner VF; Asuagbor FA; Dombi E; Fünsterer C; Kluwe L; Wenzel R; Widemann BC; Friedman JM
    Neuro Oncol; 2008 Aug; 10(4):593-8. PubMed ID: 18559970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population.
    Zöller ME; Rembeck B; Odén A; Samuelsson M; Angervall L
    Cancer; 1997 Jun; 79(11):2125-31. PubMed ID: 9179058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of neurofibromatosis type 1 in the Finnish population.
    Kallionpää RA; Uusitalo E; Leppävirta J; Pöyhönen M; Peltonen S; Peltonen J
    Genet Med; 2018 Sep; 20(9):1082-1086. PubMed ID: 29215653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.